ABT three-lens brief
Evidence-based stock research on ABT. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 8.2pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 8.2pp over 30 days.
- Analyst mean target $120.21 — 16% above current (24 analysts).
ABT closed at $103.36 (-1.78%) as of 2026-09-11. Market cap: $180.03B. P/E (trailing) 34.0. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $120.21 — 16% above current (24 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 8.2pp over 30 days.. Last quarter: Revenue $12.59B, net income $928.00M, free cash flow $7.21B.
Why three lenses on ABT, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ABTacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ABT" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ABT brief"></iframe>